Epizyme Profit Margin

Epizyme (EPZM) currently reports a profit margin of -403.17% as of June 2022. That compares with -788.6% in the prior-year period — up 48.9% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Epizyme's profit margin history and peer comparisons.

Epizyme's profit margin increased from -788.6% to -403.17% — a 48.9% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Epizyme's profit margin of -403.17% is lower than the Healthcare sector average of 17.63%. That is roughly 2387.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Epizyme's current -403.17% should be judged against Healthcare norms (sector average: 17.63%) and against EPZM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -403.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Epizyme, and consider following EPZM for alerts when major investors trade the stock.